Navigation Links
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
Date:5/19/2009

r doctor.

IMPORTANT SAFETY INFORMATION FOR PROFESSIONALS ABOUT RISPERDAL(R) CONSTA(R)

WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. RISPERDAL(R) CONSTA(R) (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Events (CAEs): CAEs, including fatalities, have been reported in elderly patients with dementia-related psychosis taking oral risperidone in clinical trials. The incidence of CAEs with risperidone was significantly higher than with placebo. RISPERDAL(R) CONSTA(R) is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including RISPERDAL(R) CONS
'/>"/>

SOURCE Janssen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
4. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Noser Health and Netcetera ... deliver new platform   ... data transaction platform, announced today strategic partnerships with ... and bring to market its global health data transaction ... "Our business model is built on trust, neutrality, impact ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., ... of cancer, today announced the filing of a registration ... Exchange Commission (SEC) relating to a proposed initial public ... to be offered and the price range for the ... list its common stock under the symbol "CTMX" on ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... their peers may be at a greater risk for injury, potentially because they ... a University of Pittsburgh Graduate School of Public Health analysis discovered. , ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... On Saturday, ... A Mission” at the Adams County Fairgrounds in Mendon, IL. The purpose behind this ... districts of Mendon and neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband use oxygen therapy ... Ky. “I thought there could be a comfortable way to prevent the irritation, so ... Ear Protector offers a more secure way to anchor the cannula tubing used in ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... medical professional association for physicians and allied health professionals dedicated to using ... Foundation, announced today the establishment of the Lifestyle Medicine Lifetime Achievement and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... by drug researchers has revealed that enabling controlled doses of ... //would serve a dual purpose – of bringing down the ... for a year will come down drastically. , ,National ... perhaps the first ever cost-benefit study of a prison methadone ...
... to information by the Canadian government a confirmed case of ... found. // ,The case was of a 6-year-old ... through a national surveillance program for mad-cow disease. ,In ... of Canadian beef. Tissues in which BSE is known to ...
... According to a Johns Hopkins University behavioral neuroscientist evidence is ... neurotransmitter when acting in the brain. // The study was ... the same direction is an article by Gregory Ball, professor ... university's Krieger School of Arts and Sciences, to be published ...
... rescue group has raised concerns over swans and other wild birds ... //. Despite pleas from wildlife rescue groups, Canada geese, peregrine falcons ... attempts of Salisbury Wildlife Rescue workers to save a swan (found ... up in vain. The bird had to be eventually destroyed by ...
... lack of sleep in children, could lead to obesity. ... faculty of medicine studied 422 grade school students aged ... waist size of each participant. ,They also ... through phone interviews with their parents, reported health portal ...
... the country focuses on headline-grabbing diseases, hemophilia, a little known ... with over 50,000 people affected. // ,World ... global effort to secure appropriate care and treatment for a ... by a defect in the genes. ,"The disease ...
Cached Medicine News:Health News:Cost-Benefit Economics of Methadone for prisoners 2
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
... Topical, Bactericide, Microbicide for professional ... technology in skin disinfectants combining quaternary ... a synergistic blend of emollients and ... and gram-positive organisms tested in 30 ...
... bonds with the skin ... germ-killing field. In addition ... antimicrobial effect, HIBICLENS' non-drying, ... promotes compliance with the ...
... solution, allows the user to prep one ... in less than 2-minutes. It also utilizes ... surgical scrubbing and healthcare personnel handwashing. ACTIPREP ... provide a tacky surface for drapes to ...
Medicine Products: